News Merck axes hepatitis C drug development Focus shifts to Keytruda amid competition from Gilead and shrinking market.
News Janssen axes hep C development with Achillion Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.
News AbbVie, Gilead target sick hepatitis C patients in EU Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News US authorities probe marketing of J&J drugs US authorities suspicious over marketing, rebates and payment support programmes.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
